Xencor to Host Webcast to Review Fourth Quarter and Full Year 2023 Financial Results and Provide Vudalimab Clinical Update

Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced that it will report financial results for the fourth quarter and full year 2023 after the market closes on Tuesday, February 27, 2024.

Xencor management will host a webcast and conference call the same day at 4:30 p.m. ET (1:30 p.m. PT) to discuss financial results, provide a corporate update and provide a clinical update of vudalimab (PD-1 x CTLA-4) in metastatic castration-resistant prostate cancer (mCRPC).

The live webcast may be accessed through “Events & Presentations” in the Investors section of the Company’s website, located at investors.xencor.com. Telephone participants may register to receive a dial-in number and unique passcode that can be used to access the conference call. A recording will be available for at least 30 days.

About Vudalimab

Vudalimab is an XmAb bispecific antibody that is designed to promote tumor-selective T-cell activation and potentially improve the therapeutic index of combination immunotherapies. Vudalimab is engineered with high specificity to target T cells that express both the immune checkpoint receptors PD-1 and CTLA-4. In a Phase 1 study, vudalimab was generally well tolerated and demonstrated encouraging clinical activity.

Xencor is conducting a Phase 2 clinical study of vudalimab in patients with metastatic castration-resistant prostate cancer (mCRPC) plus chemotherapy for certain patient populations; a Phase 2 clinical study in patients with clinically defined high-risk mCRPC; and a Phase 1b/2 clinical study evaluating vudalimab plus standard-of-care chemotherapy as a first-line treatment in patients with advanced non-squamous, non-small cell lung cancer.

About Xencor, Inc.

Xencor is a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of patients with cancer and autoimmune diseases. More than 20 candidates engineered with Xencor's XmAb technology are in clinical development, and three XmAb medicines are marketed by partners. Xencor's XmAb engineering technology enables small changes to a protein's structure that result in new mechanisms of therapeutic action. For more information, please visit www.xencor.com.